CD274 and non-small cell lung carcinoma: Their findings demonstrated that deglycosylation significantly enhanced anti-PD-L1 antibody binding, improving both signal intensity and predictive accuracy for checkpoint inhibitor response in a cohort of 44 NSCLC patients.